沃森生物涨2.02%，成交额1.60亿元，主力资金净流出402.65万元

Core Viewpoint - Watson Bio's stock has shown fluctuations with a recent increase of 2.02%, but the year-to-date performance indicates a decline of 3.73% [1] Financial Performance - For the first half of 2025, Watson Bio reported revenue of 1.154 billion yuan, a year-on-year decrease of 19.47% [2] - The net profit attributable to shareholders for the same period was 43.16 million yuan, down 74.69% year-on-year [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 117,300, a rise of 3.73% from the previous period [2] - The average number of circulating shares per shareholder decreased by 3.88% to 13,268 shares [2] Dividend Distribution - Since its A-share listing, Watson Bio has distributed a total of 403 million yuan in dividends, with 47.98 million yuan distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the largest circulating shareholder is E Fund's ChiNext ETF, holding 40.27 million shares, a decrease of 1.0618 million shares from the previous period [3] - The third-largest shareholder is the China National Bio-Medical Index A, holding 26.98 million shares, down by 2.1952 million shares [3] - The fifth-largest shareholder is the Southern CSI 500 ETF, which increased its holdings by 3.1893 million shares to 23.81 million shares [3]